Recent cost reduction in genetic testing and advances in analytics have enabled the successful establishment of several large-scale biorepositories collecting samples linked to phenotype and health data. Health systems, universities, and private organizations are increasingly investing in biobanking as a means to foster research, develop commercial partnerships, reduce healthcare costs, and improve brand visibility. Additionally, organizations are leveraging biobank resources to return clinical genetic test results to participants. This session will explore the advantages and pitfalls common to emerging biobank initiatives in the context of regulatory requirements, research endeavors, and personalized medicine.
Perspective on Establishing a Biorepository for Clinical and Research Use
Kristy Crooks, PhD, University of Colorado, Aurora, CO, USA
Profiling the DNA Damage Repair Capacity of High Grade Serous Ovarian Tumors using Patient-Derived Organoids
Sarah Hill, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA
Objectives:
- Describe the potential of 3D-organoids technology for clinical applications in infectious diseases, genetic diseases, tumor modeling and biobanking.
- Review the importance and clinical utility of biobanks.
- Discuss the regulatory aspects of maintaining a CLIA certified biobank and the return of results in a clinical setting..
Duration: 1.00 hr
Recording Date: November 7, 2019
CME/CMLE credit: 1.00 hr
Last day to purchase course and CE claim credit: December 24, 2022
